BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 29362811)

  • 1. Efficacy of Omalizumab Treatment with Concomitant Antihistamines as Needed for Moderate, Refractory Chronic Spontaneous Urticaria.
    Nettis E; Cegolon L; Macchia L; Zaza I; Calogiuri G; Di Leo E
    Acta Derm Venereol; 2018 Apr; 98(4):446-448. PubMed ID: 29362811
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness and safety of omalizumab in a patient with chronic urticaria and hepatitis C.
    Leiva-Salinas M; Francés L; Marin-Cabanas I; Arribas Granados MP; Silvestre JF
    J Eur Acad Dermatol Venereol; 2015 May; 29(5):1027-8. PubMed ID: 24629127
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of omalizumab in severe chronic spontaneous urticaria: Real life data from a Greek tertiary center.
    Kyriakou A; Trigoni A; Sotiriadis D; Patsatsi A
    Dermatol Ther; 2018 Nov; 31(6):e12739. PubMed ID: 30194796
    [No Abstract]   [Full Text] [Related]  

  • 4. Angioedema is an unfavorable factor for the response to omalizumab in chronic spontaneous urticaria: A retrospective study.
    Serarslan G; Uzun M; Doğramacı AÇ; Çelik E
    Dermatol Ther; 2019 Jan; 32(1):e12752. PubMed ID: 30238582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Chronic Urticaria": Recommendations From an Allergist and Immunologist.
    Awosika O; Qureshi A; Ehrlich A; Fonacier L
    Dermatitis; 2018; 29(5):292-293. PubMed ID: 30179970
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
    Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
    Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.
    Giménez-Arnau AM
    Expert Opin Biol Ther; 2017 Mar; 17(3):375-385. PubMed ID: 28125304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab for refractory chronic spontaneous urticaria during concurrent immunomodulatory therapy for multiple sclerosis.
    Syrigos N; Grapsa D; Syrigou E
    Eur Ann Allergy Clin Immunol; 2017 Nov; 49(6):286-287. PubMed ID: 29249139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term management of chronic spontaneous urticaria with omalizumab.
    Pinto Gouveia M; Gameiro A; Pinho A; Gonçalo M
    Clin Exp Dermatol; 2017 Oct; 42(7):735-742. PubMed ID: 28649751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab use during pregnancy for CIU: a tertiary care experience.
    Cuervo-Pardo L; Barcena-Blanch M; Radojicic C
    Eur Ann Allergy Clin Immunol; 2016 Jul; 48(4):145-6. PubMed ID: 27425170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Refractory Chronic Spontaneous Urticaria with Adalimumab.
    Bangsgaard N; Skov L; Zachariae C
    Acta Derm Venereol; 2017 Apr; 97(4):524-525. PubMed ID: 27840884
    [No Abstract]   [Full Text] [Related]  

  • 12. Self-reported hair loss in patients with chronic spontaneous urticaria treated with omalizumab: an under-reported, transient side effect?
    Konstantinou GN; Chioti AG; Daniilidis M
    Eur Ann Allergy Clin Immunol; 2016 Sep; 48(5):205-7. PubMed ID: 27608479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical practice guideline for diagnosis and management of urticaria.
    Kulthanan K; Tuchinda P; Chularojanamontri L; Chanyachailert P; Korkij W; Chunharas A; Wananukul S; Limpongsanurak W; Benjaponpitak S; Wisuthsarewong W; Aunhachoke K; Wessagowit V; Chatchatee P; Wattanakrai P; Jirapongsananuruk O; Klaewsongkram J; Noppakun N; Vichyanond P; Suthipinittharm P; Ruxrungtham K; Singalavanija S; Ngamphaiboon J
    Asian Pac J Allergy Immunol; 2016 Sep; 34(3):190-200. PubMed ID: 27690471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
    Ghazanfar MN; Holm JG; Thomsen SF
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
    Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
    Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What are the effects of omalizumab in refractory chronic spontaneous urticaria?
    López M; Navajas-Galimany L
    Medwave; 2015 Dec; 15 Suppl 3():e6346. PubMed ID: 26731420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes in urticarial vasculitis treated with omalizumab: case report.
    Cherrez-Ojeda I; Vanegas E; Felix M; Mata VL; Cherrez A
    BMC Dermatol; 2018 Oct; 18(1):8. PubMed ID: 30359231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab-induced triphasic anaphylaxis in a patient with chronic spontaneous urticaria.
    Gönül M; Özenergün Bittacı A; Ergin C
    J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):e135-e136. PubMed ID: 26446412
    [No Abstract]   [Full Text] [Related]  

  • 19. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
    Metz M; Ohanyan T; Church MK; Maurer M
    J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining Omalizumab with Another Biotherapy.
    Fougerousse AC; Becherel PA; Pallure V; Boyé T; Reguiai Z; Gabison G; Barthelemy H; Badaoui A; Mahé E; Livideanu CB;
    Acta Derm Venereol; 2019 Apr; 99(4):448-449. PubMed ID: 30723874
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.